Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics

Annals of Allergy, Asthma and Immunology

Volumn 85, Issue 1, 2000, Pages 40-45

  Pauls, John D ^a   Simon, Ronald A ^b   Daffern, Pamela J ^c   Stevenson, Donald D ^b  

^a Allergy Associates Medical Group Inc   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LIPOXYGENASE INHIBITOR; ZILEUTON;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHOSPASM; BRONCHUS REACTIVITY; CLINICAL ARTICLE; DESENSITIZATION; DRUG EFFECT; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0033856324     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62432-5     Document Type: Article

References (24)

1. Sensitivity to aspirin and nonsteroidal antiinflammatory drugs
2. Aspirin-sensitive rhinosinusitis/asthma: Spectrum of adverse reactions to aspirin
3. Aspirin intolerance in asthma-detection by challenge
4. Oral challenges to detect aspirin and sulfite sensitivity in asthma
5. Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation
6. The role and contribution of leukotrienes in asthma
7. Treatment of asthma with drugs modifying the leukotriene pathway
8. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy
9. The role of leukotriene modifiers in the treatment of asthma
10. Antileukotrienes in the treatment of asthma
11. Leukotriene inhibitors and antagonists in asthma
12. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics
13. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects
14. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asth-matic subjects
15. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics
16. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078
17. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma
18. The pivotal role of 5-lipoxygenase products in the reaction of aspirinsensitive asthmatics to aspirin
19. Aspirin desensitization in aspirin sensitive asthmatic patients: Clinical manifestations and characterization of the refractory period
20. Urinary leukotriene E4 levels during early and late asthmatic responses
21. The potent and selective sulfidopeptide leukotriene antagonist, SK and F 104353, inhibits aspirin-induced asthma
22. The leukotriene receptor antagonist MK-0679 blocks airway obstruction induced by bronchial provocation with lysine-aspirin in aspirin-sensitive asthmatics
23. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirinsensitive asthmatics during reaction to aspirin
24. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients